Immunogenicity Evaluation of Six Key Antigens of Mycoplasma pneumoniae in BALB/c Mice
Vaccines · 28.01.2026 · 14 (2) · 133
DOI: 10.3390/vaccines14020133 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vaccines, online erschienen am 28.01.2026. Verfasst von Luxia Huang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming 650118, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Li qianqian, The Medical and Health Science and Technology Innovation Project of the Chinese Academy of Medical Sciences, Yunnan Province Academician and Scientific and Technological Leadership Talent Special Project.
Abstract (Originalsprache)
Background/Objective: Mycoplasma pneumoniae (MP) remains a significant pathogen causing respiratory tract inflammation, particularly in the elderly and children under 5 years old. The lack of an effective vaccine is primarily attributed to the absence of well-defined immunological targets. This study systematically evaluated the immunological characteristics of six key MP proteins to facilitate vaccine development.
Methods
We constructed recombinant plasmids (pET30a-CARDS/P1/P40-90/P30/P116/MPN133), expressed them in Escherichia coli, and evaluated their immunogenicity and immune reactivity against MP infection in BALB/c mice.
Results
Six proteins induced strong antibody responses. Sera from all protein-immunized groups exhibited MP growth inhibitory activity, with P116 and MPN133 showing more pronounced inhibitory effects. After MP challenge, lung histopathological findings demonstrated that, except for the P1 group, the lung pathological scores of the protein-immunized groups were lower than those of the PBS control group, and the lung injury in the CARDS, P116 and MPN133 groups was significantly alleviated.
Conclusions
The six recombinant proteins demonstrate good immunogenicity. Among them, CARDS induces a strong primary antibody response, while P116 and MPN133 elicit potent anti-MP antibodies. In addition, CARDS, P116 and MPN133 significantly alleviate lung pathological damage (n = 6, p < 0.01), indicating that these three proteins have greater potential as MP vaccine targets among the six candidate proteins.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming 650118, China.
ORCID-Profile: Qianqian Li
Förderung
- Li qianqian
- The Medical and Health Science and Technology Innovation Project of the Chinese Academy of Medical Sciences
- Yunnan Province Academician and Scientific and Technological Leadership Talent Special Project
Zitieren
APA
Huang, L., Zhang, H., Xiao, H., Li, Z., & Li, Q. (2026). Immunogenicity Evaluation of Six Key Antigens of Mycoplasma pneumoniae in BALB/c Mice. Vaccines, 14(2), 133. https://doi.org/10.3390/vaccines14020133
Vancouver
Huang L, Zhang H, Xiao H, Li Z, Li Q. Immunogenicity Evaluation of Six Key Antigens of Mycoplasma pneumoniae in BALB/c Mice. Vaccines. 2026;14(2):133. doi:10.3390/vaccines14020133
BibTeX
@article{Huang2026,
author = {Huang, Luxia and Zhang, Heng and Xiao, Hongjian and Li, Zhihua and Li, Qianqian},
title = {Immunogenicity Evaluation of Six Key Antigens of Mycoplasma pneumoniae in BALB/c Mice},
journal = {Vaccines},
year = {2026},
volume = {14},
number = {2},
pages = {133},
doi = {10.3390/vaccines14020133}
}
EUVIMED